Company ProfilePremium

Astec LifeSciences Limited

Company Profile Analysis

Tickers: ASTEC.NS, 533138.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Astec LifeSciences Limited - Company showcase

Year Founded & Workforce

1994

528 Employees

Astec LifeSciences Limited logo

Astec LifeSciences Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Astec LifeSciences Limited Overview

Astec LifeSciences is a small-cap, B2B-only Indian manufacturer of off-patent agrochemical active ingredients (technicals), intermediates and select formulations, and a contract development and manufacturing (CDMO) partner to multinational crop-science and specialty-chemical innovators. Its historical franchise is triazole fungicides — tebuconazole, propiconazole, hexaconazole and related molecules — produced at five plants in MIDC Mahad, Maharashtra. Since Godrej Agrovet took control in 2015, Astec has been repositioned toward higher-value CDMO work and herbicide chemistry, supported by a dedicated R&D centre at Rabale (2023). The 2023–2025 global agrochemical destocking and Chinese generic oversupply hit Astec unusually hard: revenue fell from ₹677 crore (FY22) to ₹381 crore (FY25) and the company has posted three consecutive annual losses. FY26 marked an inflection, with revenue up 17.5%, EBITDA breakeven, and a ₹249 crore rights issue. Its investment case now rests on CDMO ramp-up, operating leverage, and Godrej parentage.


Company's own description. In its recurring "About" boilerplate across FY25–FY27 press releases, Astec describes itself as incorporated in 1994 and engaged in manufacturing agrochemical active ingredients (technical), bulk formulations and intermediate products, with a balanced mix of exports and domestic sales, exporting to over 18 countries (2026 releases; earlier materials cited approximately 24 countries). Its January 2026 PR Newswire release positions it as a manufacturer of agrochemicals, active ingredients and pharmaceutical intermediates with flexible reactor capacities of 3 KL to 32 KL across glass-lined, stainless steel and Hastelloy systems.

What the company does. Astec runs multi-step organic synthesis in batch reactors to produce (a) technical-grade active ingredients sold to formulators and agrochemical majors (the "Enterprise" business), and (b) custom-synthesised intermediates, active ingredients and specialty chemicals manufactured to customer specifications under contract (the "Contract Manufacturing & New Products" / CDMO business). ICRA's March 2026 rationale summarises the split as technical-grade fungicides and agrochemicals in Enterprise, and agrochemical intermediates and specialty chemicals in CDMO.

Business model and revenue model. Astec's revenue is almost entirely product revenue from B2B sales; there is no subscription, licensing or royalty income disclosed. Within product revenue, two economic models coexist:

Shares derived from company segment disclosures; company/AR-based summaries report 48% Enterprise / 52% CDMO for FY26.

Value chain position. Astec sits in the upstream manufacturing tier of the crop-protection value chain: it buys key starting materials and intermediates (50–55% of raw materials imported, primarily from China, per ICRA), performs synthesis to technical grade, and sells to formulators, distributors and innovators who brand and distribute to farmers. Some backward integration into intermediates partially hedges input cost volatility. It does not operate a farmer-facing branded formulation franchise; that role within the Godrej group sits with Godrej Agrovet's crop protection business, which is also a related-party customer/supplier.

Customer types. Large agrochemical MNCs (domestic subsidiaries and overseas), Indian formulators, innovator crop-science companies (CDMO), and group companies (GAVL, GIL). Historical disclosures cite Syngenta India and Nufarm as early customers (2009) and custom-synthesis clients in Europe, Japan and the US. Specific current customer names and concentration percentages are not publicly disclosed.

End-markets. Crop protection (fungicides dominant; herbicides growing; plant-growth regulators), household insecticides (transfluthrin), and life-science/specialty intermediates via CDMO.

Independent characterisation. Astec is best understood as a sub-scale, single-site specialty chemical manufacturer that was built on a narrow, commoditising triazole portfolio and is now mid-way through a deliberate pivot to CDMO. The pivot is strategically sound — CDMO revenue has greater customer stickiness and pricing insulation — but it is capital-intensive, slow to ramp and lumpy, as evidenced by CDMO revenue swinging from ₹13.6 crore (Q2 FY26, derived) to ₹77.6 crore (Q3 FY26) within one quarter. The business carries structurally high working capital (cash conversion cycle of 263 days in FY26 per Screener), leaving it dependent on parent support and short-term debt markets during the downturn.

Strategy

Stated strategic themes (synthesised from management commentary, ICRA, and the April 2023 R&D centre launch, paraphrased):

  1. Pivot to CDMO. Become a preferred, application-agnostic manufacturing partner for innovator companies and MNCs, raising the share of higher-margin, more predictable contract revenue. Management has been selective in onboarding projects, favouring high-margin opportunities even at the cost of near-term growth.

  2. Portfolio diversification beyond triazoles. Herbicide manufacturing (since August 2021) and new products reduce dependence on a handful of generic fungicides.

  3. R&D-led process optimisation. The Rabale centre focuses on new product generation, process optimisation, scale-up and lifecycle management, with an emphasis on green chemistry; process improvements are explicitly intended to support margin expansion.

  4. Capital discipline. Capex pruned to ₹10–15 crore per annum over the medium term; focus on lifting utilisation of existing assets.

  5. Balance-sheet repair. Equity infusion via rights issue; debt prepayment; liquidation of high-cost legacy inventory.

  6. Manufacturing and ESG positioning for export customers. Promotion of safety, quality and sustainability credentials (e.g., ICSCE Dubai, January 2026).

Initiatives in the last 24 months

Medium-term financial targets / guidance. No quantitative medium-term targets (revenue, margin or ROCE) are publicly disclosed. The only forward-looking commentary is qualitative: the Chair expects the demand–supply imbalance that has persisted since 2023 to normalise over the medium term (July 2026); ICRA expects recovery momentum to sustain but margins to stay below historic levels.

Products & Services

Astec does not publish product-wise revenue, launch dates or pricing. The catalogue below is compiled from the company website (as summarised by Screener's key-points extract), ICRA, and historic disclosures. All sales are B2B; pricing model is negotiated per order/contract (not publicly disclosed).

Enterprise — Triazole and other fungicides (core franchise)

ProductClass / useTarget customerNotes
TebuconazoleTriazole fungicide (cereals, fruits, vegetables)Formulators, MNCsHistorically a flagship volume molecule
PropiconazoleTriazole fungicide (cereals, rice, turf)Formulators, MNCsLong-standing product
HexaconazoleTriazole fungicide (rice sheath blight, plantation crops)Domestic formulatorsHigh domestic relevance; also made by peers (e.g., Rallis)
DifenoconazoleTriazole fungicide (broad-spectrum)Formulators, MNCsHigher-value triazole
MetconazoleTriazole fungicide / PGR effectExport customersNiche, higher complexity
CyproconazoleTriazole fungicideExport customers—
ProthioconazoleTriazolinthione fungicideExport customersAmong the larger global triazole markets
FlutriafolTriazole fungicideExport customers—
Metalaxyl / Metalaxyl-MPhenylamide fungicide (oomycetes)FormulatorsNon-triazole diversification

Enterprise — Herbicides (diversification since 2021)

ProductClass / useNotes
QuizalofopAryloxyphenoxy-propionate (grass weeds in broadleaf crops)Produced in high-potency herbicide facility (commissioned Aug 2021)
ImazethapyrImidazolinone (soybean, pulses)—
Sulfonylurea herbicides (unspecified)ALS inhibitors, low-dose high-potencySpecific molecules not publicly disclosed

Enterprise — Other actives

ProductClass / useNotes
PaclobutrazolPlant growth regulator (triazole chemistry; mango flowering, fruit crops)Shares triazole synthesis know-how
TransfluthrinPyrethroid household insecticide AI (vaporisers, coils)Serves consumer-products customers; Godrej group adjacency
IntermediatesTriazole and other intermediatesSold externally and used captively

CDMO — Contract Development and Manufacturing Operations

Service elementDescription
Process developmentRoute scouting and optimisation at the Rabale R&D centre
Analytical and safety studiesMethod development, process safety/hazard assessments
Pilot scale-upKilo-lab to pilot campaigns
Qualification samplesCustomer validation batches
Plant designDedicated or adapted plant configuration
Commercial manufactureStarting materials, active ingredients and advanced intermediates for crop-science, life-science and consumer-product customers
Asset baseReactors of 3 KL–32 KL in glass-lined, SS and Hastelloy; two herbicide plants, one dedicated to CDMO

Named CDMO molecules and customers are confidential (not publicly disclosed). Historical milestones include the commercialisation of two new CMO products and a new production process for an Enterprise product in FY22.

As a B2B technical manufacturer, Astec does not operate farmer-facing brands.

Financial Narrative

Source: consolidated audited financials as compiled by Screener.in (FY22–FY26), cross-checked with company press releases and ICRA. Ratios marked "derived" are computed by the analyst from these figures.

Income statement

Gross profit is not publicly disclosed on a consistent basis in sources reviewed. FY25 and FY26 company-reported EBITDA are −₹60.6 crore and +₹0.5 crore respectively; the minor differences from the derived row reflect rounding and forex-gain classification. Diluted EPS equals basic for practical purposes (ESOP dilution immaterial; diluted figures not separately captured).

Revenue CAGR FY22–FY26: −9.8% (derived). Over 10 years Screener reports a +7% sales CAGR; over 5 years, −4%.

Dividends per share. No dividend was paid for FY24, FY25 or FY26 (payout 0%).

Commentary. The P&L tells a three-act story. Act one (FY22): peak revenue of ₹677 crore with a 23% operating margin, fuelled by the post-COVID agrochemical upcycle and tight Chinese supply. Act two (FY23–FY25): a collapse driven by global channel destocking, Chinese generic capacity flooding triazole markets, and erratic monsoons. Revenue fell 44% from peak to FY25, and operating leverage worked brutally in reverse — Astec's fixed-cost base (depreciation up from ₹34 crore to ₹44 crore after capex for herbicide plants and the R&D centre; finance costs quadrupling from ₹9 crore to ₹37 crore) turned a modest revenue decline into a net loss of ₹135 crore in FY25. FY25 also absorbed high-cost legacy inventory, with an ₹18.5 crore write-down in Q1 FY25 alone. Act three (FY26): revenue recovered 17.5% to ₹448 crore on volume gains in both categories, EBITDA returned to breakeven, and the net loss narrowed to ₹81 crore. The H2 FY26 run-rate was markedly better: Q3 and Q4 FY26 EBITDA of ₹4.8 crore and ₹11.8 crore. Q1 FY27 (₹84.3 crore income, EBITDA ₹0.1 crore, loss ₹18.7 crore vs ₹33.0 crore) confirms seasonal weakness persists but at structurally lower losses.

Quarterly trajectory

Q2 FY26 EBITDA derived as 9M FY26 EBITDA loss of ₹11.2 crore less Q1 and Q3 values. Q1 FY25 PAT per Simply Wall St (₹397.2 million loss); other values from company releases and Screener.

Balance sheet

Cash balances are minimal: ₹27.05 million at FY25 (Simply Wall St) and ~₹10 crore at 30 Sep 2025 (ICRA). Net debt therefore approximates total borrowings. Short-/long-term debt split, goodwill/intangibles and working capital in absolute terms were not publicly disclosed in sources reviewed. ICRA-rated instruments at Mar 2026: fund-based working capital ₹283 crore, term loan ₹100 crore (maturity 30 Apr 2028), NCD ₹49 crore, CP programme ₹300 crore (₹100 crore outstanding at rationale date), non-fund-based ₹335 crore.

Commentary. The balance sheet absorbed the downturn through debt. Borrowings rose from ₹279 crore (FY22) to ₹555 crore (FY25) as negative operating cash flow coincided with a ₹350+ crore capex cycle (FY22–FY24). Net worth fell from ₹420 crore (FY23) to ₹235 crore (FY25) — a 44% erosion — pushing debt/equity to 2.36x. The July 2025 rights issue reset the capital structure: FY26 net worth recovered to ₹391 crore, and ~₹102 crore of term debt was prepaid from rights proceeds, bringing borrowings to ₹449 crore and debt/equity to 1.15x. The completion of the capex cycle is visible in CWIP falling from ₹165 crore (FY24) to ₹20 crore (FY26).

Cash flow

Capex derived as CFO minus FCF (Screener). Dividends paid for FY22–FY23 not separately captured (small amounts).

Commentary. Astec has generated negative free cash flow in every one of the last five years, cumulatively −₹357 crore. FY26 is notable: despite EBITDA breakeven, operating cash flow was −₹81 crore because revenue recovery was back-ended (Q4 FY26 was the largest quarter) and receivables surged (debtor days rose to 202 per Screener). This is a key watch item: the rights issue funded debt reduction, but the working-capital build consumed liquidity. Management has guided capex down to ₹10–15 crore per year (per ICRA), so FCF should approach operating cash flow in FY27.

Ratios

Net debt/EBITDA not meaningful for FY24–FY26 (EBITDA ≈ zero or negative). Interest coverage from Value Research; company-reported Interest Service Coverage Ratio was −1.48x (FY25) and −0.04x (FY26). Debtors turnover discrepancy: company results show 2.35x (FY25) and 2.25x (FY26), while the FY25 Annual Report table shows 3.14x (FY25) and 2.83x (FY24), likely reflecting standalone vs consolidated or different averaging methods.

Commentary. Every return metric peaked in FY22 and troughed in FY25. The single most important operational improvement in FY26 was inventory: inventory turnover improved from 1.30x (FY24) to 3.01x (FY26) as legacy high-cost stock was liquidated — ICRA explicitly credits this for part of the margin recovery. The offsetting deterioration was receivables, with debtor days jumping to 202, pushing the cash conversion cycle to a five-year high of 263 days. Current ratio below 1.0x reflects reliance on short-term instruments (CP, working-capital lines) to fund long-gestation assets.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment (INR Cr)FY24FY25FY26

Enterprise revenue

—175.4210.2

CDMO / Contract Manufacturing & New Products revenue

—205.9237.9

Total revenue from operations

458.2381.3448.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (%) and Segment Margins & Growth (%)

Segment metricFY25FY26

Enterprise share of revenue (%)

4647

CDMO share of revenue (%)

5453

Enterprise YoY growth (%)

—19.8

CDMO YoY growth (%)

—15.5

Revenue by Segment (Quarterly)

Segment (INR Cr)Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Enterprise

36.560.146.667.051.8

CDMO & New Products

54.613.677.691.631.8

Total

91.173.7124.2158.683.6

Income Statement and Per-Share Data

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

677628458381448

Total operating expenses

522551464448453

Operating profit before other income (EBITDA ex-OI)

15477-6-66-4

Other income

1013663

EBITDA incl. other income (company basis)

16490-1-611

Depreciation and amortisation

3434364445

Operating income / EBIT (derived)

13056-37-104-46

Finance costs

921253735

Profit before tax

12135-62-141-81

Net income (PAT)

9026-47-135-81

EPS basic (INR)

40.1211.41-20.95-60.16-36.32

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

22.0-7.2-27.1-16.817.5

EBITDA margin ex-OI (%)

23.012.0-1.3-17.0-1.0

EBIT margin (%)

19.28.9-8.1-27.3-10.3

Pre-tax margin (%)

17.95.6-13.5-37.0-18.1

Net margin (%)

13.34.1-10.3-35.4-18.1

Effective tax rate (%)

2627-24-40

Financial Analysis

Metric (₹ per share)FY2024FY2025FY2026

Dividend per share

000

Income Statement

Metric (INR Cr)Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations

699994120917412515984

Total income

70.3100.595.8120.391.674.8125.5161.384.3

Company-reported EBITDA

-45.3-17.7-3.86.3-10.5-5.54.811.80.1

Net profit (PAT)

-39.7-38.6-40.4-16.1-33.0-24.4-15.7-7.7-18.7

Balance Sheet

Metric (INR Cr, at 31 March)FY2022FY2023FY2024FY2025FY2026

Total assets

897979975881942

Net fixed assets

340318386499459

Capital work-in-progress

231271652120

Other (mainly current) assets

534534424361463

Total borrowings

279341494555449

Other liabilities

22121911292102

Share capital

2020202022

Reserves

377400350215368

Shareholders' equity (net worth)

397420370235390

Key Financials

Metric (INR Cr, at 31 March)FY2025

Cash and equivalents (INR Cr)

2.7

Net debt (INR Cr)

552

Cash Flow

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

247510-8-81

Capital expenditure (derived)

104117135165

Free cash flow

-80-42-125-24-86

Investing cash flow

-104-113-135-15-4

Financing cash flow

80381252494

Dividends paid

——000

Share buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%, derived on average equity)

25.56.4-11.9-44.6-25.9

ROA (%, derived on average assets)

11.42.8-4.8-14.5-8.9

ROCE / ROIC proxy (%, Screener)

228-4-13-5

Current ratio (x)

—0.951.000.930.88

Debt / equity (x)

0.700.811.342.361.15

Net debt / EBITDA (x)

1.84.4———

Interest coverage, EBIT basis (x)

14.372.69-1.45-2.84-1.35

Asset turnover (x)

0.850.660.470.420.49

Debtor days

14890135141202

Inventory days

176268224196169

Payable days

179161102100107

Cash conversion cycle (days)

145197256237263

Inventory turnover (x, company)

——1.302.143.01

Revenue by Region

Region (INR Cr)FY24FY25FY26

Exports (outside India)

—259.9277.4

Domestic (India)

—121.4170.7

Total

458.2381.3448.1

Revenue by Region (%) and Region Margins & Growth (%)

Region metric (INR Cr)FY25FY26

Exports share (%)

6862

Domestic share (%)

3238

Exports YoY growth (%)

—6.7

Domestic YoY growth (%)

—40.6

Revenue by Region (Quarterly)

Region (INR Cr)Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Exports

69.696.045.941.086.3103.733.3

Domestic

24.323.545.232.237.954.950.3

Valuation Snapshot

MetricValue

Last close (16 Oct 2026)

₹710

52-week high / low

₹942 / ₹512

Market cap

~₹1,583 crore

Book value per share

~₹175

Rights issue price (Jul 2025)

₹890

2024 open offer price

₹1,094.96

Return metric (% CAGR, Screener)

1 year

Stock price CAGR

-3

Capital Markets

MetricAstecDhanukaUPLPI IndustriesSumitomo Chem. IndiaSharda Cropchem

P/E (x)

—19.656.431.455.216.9

P/B (x)

4.054.151.735.129.612.06

EV/EBITDA (x)

—13.09.219.537.17.3

Debt/equity (x)

1.150.041.020.020.020.01

Astec Valuation Details

Astec valuation (derived, Oct 2026)Value

Enterprise value (INR Cr)

~2,022 (market cap 1,583 + FY26 debt 449 − cash ~10)

EV / TTM sales (x)

~4.6

EV / TTM EBITDA (x)

NM (TTM EBITDA near zero)

Credit Ratings

AgencyInstrumentRatingOutlookDate

ICRA

Long-term fund-based (CC ₹283 crore, TL ₹100 crore)

[ICRA]AA-

Negative

24 Mar 2026

ICRA

NCD ₹50 crore

[ICRA]AA-

Negative

24 Mar 2026

ICRA

Short-term non-fund-based ₹335 crore

[ICRA]A1+

—

24 Mar 2026

ICRA

Commercial paper ₹300 crore

[ICRA]A1+

—

24 Mar 2026

India Ratings & Research

NCDs

IND AA-

Not captured

Jun 2026

Moody's / S&P / Fitch (international)

—

Not rated

——

Maturity Item Details

Maturity itemAmount (INR Cr)Due

NCD (INE563J08023, 8.90%, unsecured)

49

25 Mar 2027

Total long-term repayments in FY27 (incl. NCD)

~90

FY27 (to be refinanced via fresh NCDs / GAVL ICDs per ICRA)

Term loan (rated limit)

100

Final maturity 30 Apr 2028

Commercial paper

50–100 per month rollover

Rolling, ≤1 year

Undrawn working-capital buffer

~317

Available (Dec 2025)

Analyst Conclusions

Management guidance. No numeric guidance. The Chair expects industry normalisation over the medium term; management attributes recent gains to product mix, margins in both categories, and capacity utilisation. ICRA expects recovery momentum to continue with margins below historic peaks.

Consensus growth expectations. No reliable current consensus available (see 21.3).

Bull case

  1. Operating leverage is already visible. EBITDA swung from −₹60.6 crore (FY25) to +₹0.5 crore (FY26) on just ₹67 crore of incremental revenue; H2 FY26 EBITDA of ₹16.6 crore annualises to well above breakeven. A return toward FY22-like revenue (₹600+ crore) on a ₹45 crore depreciation and ₹35 crore interest base could restore meaningful profits.

  2. Structural trade tailwinds. The India–China tariff differential in the US and China's VAT rebate removal on technicals directly improve Astec's competitiveness in its core export markets.

  3. Parent backstop and optionality. GAVL's ₹200 crore infusion, 67% stake, ICD support and the re-alignment under Godrej Chemicals' CEO reduce solvency risk and create potential strategic upside.

Bear case

  1. Cash, not EBITDA, is the problem. FY26 operating cash flow was −₹81 crore with debtor days at 202; until receivables normalise, debt will not fall organically.

  2. CDMO lumpiness and opacity. CDMO revenue fell 42% YoY in Q1 FY27; with no disclosed pipeline, customer count or contract tenure, investors cannot underwrite recovery durability.

  3. Valuation already discounts recovery. At ~4x book and ~4.6x EV/sales for a loss-making company with Negative-outlook credit, downside risk is significant if H2 FY27 fails to replicate H2 FY26.

Catalysts and monitorables (next 12 months)

26 Oct 2026: Q2 FY27 results — CDMO recovery vs Q2 FY26's ₹13.6 crore trough; EBITDA trajectory.

  • H2 FY27 seasonality: whether Q3–Q4 FY27 exceed H2 FY26's ₹16.6 crore EBITDA.

  • Receivables and operating cash flow at H1 FY27 balance sheet.

  • Refinancing of the ₹49 crore NCD due March 2027 and the ICRA surveillance review (~March 2027) — any outlook change to Stable.

  • RPT volumes with GAVL/GIL against approved limits.

  • Any corporate-action announcement by the parent (unconfirmed; monitor exchange disclosures).

  • Chinese triazole pricing and US tariff policy.

  • New molecule commercialisation from the Rabale R&D centre.

Analyst verdict

Astec LifeSciences is a classic cyclical-plus-transition story whose cycle appears to have turned but whose transition remains unproven. The evidence of trough-passing is credible: revenue recovered 17.5% in FY26, legacy inventory has been flushed (inventory turnover more than doubled from FY24), EBITDA has been non-negative for four consecutive quarters, and the rights issue removed the immediate solvency overhang by cutting debt/equity from 2.36x to 1.15x. Industry data — the end of global destocking, Indian tariff advantages in the US and higher Chinese export costs — supports continued volume recovery.

What remains unproven is whether Astec can convert recovery into durable returns on capital. The CDMO business, now over half of revenue, is strategically correct but operationally erratic, and management provides almost none of the disclosure (pipeline, customer count, contract tenure, R&D spend) that investors routinely receive from larger Indian CDMO peers. Working capital is the other weak link: a 263-day cash conversion cycle means each rupee of growth absorbs cash, and FY26's −₹81 crore operating cash flow illustrates the problem even in a recovery year. Credit agencies have rightly retained a Negative outlook.

The decisive variable is the parent. Godrej Agrovet's steadily rising stake, its ₹200 crore rights subscription and the April 2026 appointment of the Godrej Chemicals CEO as chair signal strategic commitment; Astec's credit and liquidity rest substantially on that support. For equity holders, however, the current valuation (~4x book, ~4.6x EV/sales, loss-making) already embeds a meaningful recovery and arguably some corporate-action optionality.

Verdict: Fundamentally improving but speculative. The risk–reward is balanced-to-unfavourable at current prices for fundamentals-driven investors; conviction would require two or three consecutive quarters of positive PAT, normalising receivables and greater CDMO disclosure. Credit investors are better protected than equity holders, given parental backing.


SOURCES REGISTER (primary and secondary references used)

  • NSE/BSE filings: Q1 FY27 press release (31 Jul 2026) — nsearchives.nseindia.com/corporate/ASTEC_31072026203640_BSENSEPRESSRELEASE31072026.pdf

  • Q3 FY26 press release (30 Jan 2026) — nsearchives.nseindia.com/corporate/ASTEC_30012026204330_BSENSEPRESSRELEASE30012025.pdf

  • Q4 FY26 press release (27 Apr 2026) — bseindia.com/xml-data/corpfiling/AttachHis/4d58e25a-b30c-409b-9012-adcb222412f4.pdf

  • Q2 FY25 press release (25 Oct 2024) — bseindia.com (corpfiling cc8662e9)

  • Integrated governance filing (30 Apr 2026) — nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_GOVERNANCE_154562_30042026115550_iXBRL_WEB.html

  • Clean Max Andes divestment intimation (9 Mar 2026) — nsearchives.nseindia.com/corporate/ASTEC_09032026193323_BSENSECleanmax.pdf

  • NCD disclosure Annex XIV-B (25 Apr 2026) — nsearchives.nseindia.com/content/debt/WDM/ASTEC_25042026113325_Disclosure_XIV-B.pdf

  • Anurag Roy resignation (23 Sep 2024) and director-change intimation (29 Aug 2025) — BSE/NSE

  • ICRA rating rationale, 24 Mar 2026 — icra.in/Rating/GetRationalReportFilePdf?id=141823; earlier rationales 25 Mar 2025, 7 Aug 2024, Sep 2017

  • ICRA Indian Agrochemical Industry reports (Apr 2025; Feb 2026)

  • SEBI open offer documents (Aug 2015; Apr–Dec 2024)

  • Screener.in consolidated financials and shareholding — screener.in/company/ASTEC/consolidated/

  • Value Research key ratios and peer comparison; Pocketful peer multiples; Simply Wall St; TipRanks; Tracxn

  • Rights issue details: Chittorgarh, FilingReader, Zerodha TradingQnA

  • Leadership transition coverage: Reuters via Stockopedia; Chemical Weekly; The Machine Maker; Board Stewardship

  • Peer results: PI Industries FY26 presentation; Rallis India FY26 press release; India Pesticides FY26 coverage

  • Market data: AgbioInvestor via AgriBusiness Global; S&P Global via Chemical Week; Rubix Data Sciences; Crisil Ratings via Outlook Business

  • Company PR Newswire release (16 Jan 2026); R&D centre launch coverage (Apr 2023)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRole / categoryBoard sinceAge (DOB)Background

Vishal Sharma

Chairperson; Non-Executive, Non-Independent

13 Apr 2026

—

Executive Director & CEO (Chemicals), Godrej Industries Ltd

Arijit Mukherjee

Executive Director & Chief Operating Officer

ED from 13 Apr 2026 (term to 12 Apr 2029); COO since 2016

—

20+ years in agri-inputs; with Godrej Agrovet since 2005 in sales and marketing operations; oversees manufacturing and B2B/CDMO business

Burjis N. Godrej

Non-Executive, Non-Independent

25 Jul 2022

33 (14 Dec 1992)

Executive Director, Godrej Agrovet; Astec MD until 13 Apr 2026; GAVL Chairperson from 14 Aug 2026

Ashok V. Hiremath

Non-Executive, Non-Independent (founder)

25 Jan 1994

71 (31 May 1955)

Founder-promoter; chairs Risk Management Committee; member of Audit Committee

Sunil Kataria

Non-Executive, Non-Independent

1 Sep 2025

58 (7 May 1968)

CEO & MD (designate at appointment), Godrej Agrovet; formerly with Godrej Consumer Products; chairs Stakeholders Relationship Committee

R. R. Govindan

Independent

30 Jan 2020

72 (13 Aug 1954)

Chairs Audit Committee and Nomination & Remuneration Committee

Nandkumar Dhekne

Independent

18 Dec 2020 (re-appointed 18 Dec 2025)

69 (2 Sep 1957)

Member, Stakeholders Relationship Committee

Anjali Rajesh Gupte

Independent

18 Dec 2020 (re-appointed 18 Dec 2025)

56 (3 Sep 1970)

Member, Audit and NRC

Ganapati D. Yadav

Independent

17 Sep 2024

74 (14 Sep 1952)

Eminent chemical engineer (widely reported former Vice-Chancellor, ICT Mumbai); six listed directorships

Mathew Eipe

Independent

13 Apr 2026 (term to 6 Jun 2027)

—

Joined Godrej Soaps in 1977; ED & President (Chemicals), Godrej Industries from 2001 until retirement in 2013; Independent Director of Godrej Industries

“—” = not publicly disclosed.

Executive Leadership Team

NameTitleSinceNotes

Arijit Mukherjee

ED & COO

COO 2016; ED Apr 2026

Basic salary range ₹35–42 lakh p.a. plus allowances, variable pay, ESOPs and retention payouts (postal ballot notice, June 2026)

Deepak Jawaharlal Ochani

Chief Financial Officer

1 Apr 2026

Chartered Accountant

Tejashree Pradhan

Company Secretary & Compliance Officer

—

FCS 7167

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

3 May 2024

CFO K. Suryanarayan resigns

Appointed May 2023; one-year tenure

4 Oct 2024

Independent Director Dr. B. N. Vyas resigns

Cited advancing age

25 Oct 2024

CEO & WTD Anurag Roy exits

Had been re-appointed for 3 years from July 2024; no material reasons cited

1 Apr 2025

Burjis Godrej re-appointed (as MD, per governance filing)

Led the company through recovery

31 Aug 2025

Balram Singh Yadav (NED) resigns

Superannuation from Godrej Agrovet

1 Sep 2025

Sunil Kataria joins board

GAVL CEO-designate

6 Mar 2026

CFO Mugdha Khare exits

Resignation announced 30 Jan 2026

1 Apr 2026

Deepak Ochani becomes CFO

Planned succession

13 Apr 2026

Nadir Godrej retires as Chair; Vishal Sharma Chair; Burjis Godrej steps down as MD; Arijit Mukherjee ED; Mathew Eipe ID

Group-wide generational succession plan

5 Jun 2026

GM–HR Vijayalakshmi Iyer resigns

Senior management

Shareholding Trend

Holder category (%)Sep 2024Mar 2025Sep 2025Mar 2026Sep 2026

Promoter and promoter group

66.7470.8772.4271.9771.97

Foreign institutional investors

0.530.250.000.030.02

Domestic institutional investors

4.504.344.013.333.34

Public / others

28.2024.5323.5724.6724.67

Competitive Landscape

Key Competitors

CompetitorOverlap with AstecLatest annual revenue (INR Cr)Positioning vs Astec

PI Industries

Agchem CSM/CDMO for innovators; process chemistry

6,714 (FY26)

Scale leader in Indian agchem CDMO; 25% EBITDA margin; net cash

UPL

Global generics including fungicides

Not compiled

Global generic giant; vastly larger distribution

Rallis India (Tata)

Hexaconazole and generic technicals; B2B exports and CSM

2,897 (FY26)

Domestic branded + B2B; record 12.5% EBITDA margin in FY26

India Pesticides

Fungicide/herbicide technicals for export and domestic

1,057 (FY26)

Fast-growing peer of similar heritage; 18% EBITDA margin; EU fungicide approval

Sharda Cropchem

Generic registrations/marketing (customer and competitor)

5,357 (TTM)

Asset-light registrant; sources from Indian/Chinese manufacturers

Dhanuka Agritech

Domestic formulations

1,953 (TTM)

Branded domestic; low overlap on technicals

Bayer CropScience (India)

Triazole fungicide formulations in India

5,595 (TTM)

Innovator/brand owner; potential customer

Sumitomo Chemical India

Domestic formulations and technicals

3,245 (TTM)

MNC subsidiary; potential customer

Chinese triazole producers (multiple)

Tebuconazole, propiconazole, difenoconazole etc.

Not compiled

Primary price-setters; source of the 2023–25 price collapse (ICRA)

Navin Fluorine, Anupam Rasayan, SRF, Aarti Industries

Specialty-chemical CDMO for agro/pharma innovators

Not compiled

Larger CDMO platforms competing for the same innovator programmes

Gharda Chemicals (unlisted)

Technical manufacturing for export

—

Integrated Indian technical manufacturer

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricAstec LifeSciencesPI IndustriesRallis IndiaIndia Pesticides

Revenue (INR Cr)

4486,7142,8971,057

Revenue growth YoY (%)

17.5-15.88.827.6

EBITDA margin (%)

0.125.012.518.0

Net margin (%)

-18.119.76.411.4

R&D intensity (% of revenue)

—

Not compiled

Not compiled

Not compiled

Debt/equity (x)

1.15

~0.02

Not compiled

Not compiled

“—” = not publicly disclosed.

Company Snapshot

$51.7M

Revenue

528

Employees

1994

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Strong parent support. GAVL raised its stake from 52.28% (Dec 2015) to 67.03% (Dec 2025), infused ~₹200 crore via the 2025 rights issue, and provides ICDs as needed (ICRA, Mar 2026).
  • Refinancing access despite losses. CP issued at 6.73–7.00% in Oct–Nov 2025 and [ICRA]A1+ short-term rating maintained.
  • Restored capital base. Net worth rose from ₹235 crore (FY25) to ₹391 crore (FY26); debt/equity fell from 2.36x to 1.15x.
  • Operating recovery evidence. FY26 revenue +17.5% and EBITDA breakeven; Q1 FY27 EBITDA positive versus −₹10.5 crore a year earlier.
  • Established triazole franchise with MNC clientele. Two-decade track record recognised by ICRA as a credit strength.
  • Completed capex cycle. CWIP fell from ₹165 crore (FY24) to ₹20 crore (FY26); maintenance capex guided at ₹10–15 crore p.a., freeing cash for working capital and debt service.

Weaknesses

  • Persistent losses. Net losses of ₹46.9 crore (FY24), ₹134.7 crore (FY25), ₹80.9 crore (FY26) and ₹18.7 crore (Q1 FY27).
  • Negative free cash flow every year FY22–FY26 (cumulative −₹357 crore); FY26 CFO −₹81 crore despite EBITDA breakeven.
  • Working-capital intensity. Cash conversion cycle of 263 days and debtor days of 202 in FY26 (Screener).
  • Product concentration. ICRA highlights dependence on a few triazole generic molecules.
  • Sub-scale and single-site. ₹448 crore revenue, all manufacturing at Mahad.
  • Management churn and disclosure gaps. Three CFOs and two CEO/MD changes in ~24 months; no earnings calls since 2022 and no pipeline or R&D metrics disclosed.

Opportunities

  • CDMO ramp. CDMO already ~52–53% of FY26 revenue; Q3–Q4 FY26 CDMO revenue (₹77.6 crore and ~₹91.6 crore) shows capacity to scale.
  • China+1 and tariff tailwinds. 18% US tariff on Indian vs 35% on Chinese agrochemicals (ICRA, Feb 2026).
  • China VAT rebate removal. Raises Chinese export costs for technicals/intermediates, improving Astec's relative cost position.
  • Herbicides. Indian herbicide exports growing at a 20% CAGR (FY20–FY25), aligning with Astec's two herbicide plants.
  • Operating leverage. With a largely fixed cost base (depreciation ₹45 crore, finance costs ₹35 crore), revenue returning toward FY22 levels would sharply improve profitability.
  • Godrej Chemicals synergy. Vishal Sharma's chairmanship and ₹105 crore RPT limit with GIL could open cross-selling and shared-asset opportunities.

Threats

  • Chinese oversupply. ICRA expects pricing pressure on key products to continue amid unprecedented Chinese competition.
  • CDMO lumpiness. CDMO revenue fell 41.8% YoY in Q1 FY27; loss of any major programme could reverse progress.
  • Refinancing and liquidity. ~₹90 crore of long-term debt due in FY27 including the ₹49 crore NCD (March 2027), plus monthly CP rollovers of ₹50–100 crore.
  • Rating downgrade risk. ICRA retains Negative outlook; continued earnings pressure is a stated downgrade trigger.
  • Agro-climatic and FX risk. Monsoon dependence for domestic sales; ~62% export share exposes margins to INR movements (partially hedged by 50–55% imported raw materials).
  • Regulatory/ESG risk. Tightening rules on hazardous actives and chemical-site safety (ICRA environmental considerations).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
23–24 Apr 2025Q4 FY25: revenue ₹119.5 crore (−22% YoY), loss ₹16.1 crore; FY25 loss ₹134.7 croreTrough year confirmed; sequential EBITDA improvement noted
11 Jun 2025India Ratings rating updateSecond rating agency on NCDs
24 Jun 2025Board approves rights issue up to ₹250 crore; stock up ~12.6% intradayCapital structure repair
2 Jul 2025Letter of Offer: 28,01,673 shares at ₹890, ratio 1:7Terms set
4 Jul 2025Rights record date; FY25 Annual Report disclosures—
14–28 Jul 2025Rights issue openParent underwrites majority (~₹200 crore)
28 Jul 2025Q1 FY26: income ₹91.6 crore (+30% YoY), EBITDA loss ₹10.5 crore, loss ₹33.0 crore; stock −6.8% to ₹838.80Recovery begins YoY
29 Jul–1 Aug 2025Rights allotment and listingNet worth restored
29 Aug 2025B. S. Yadav resigns (eff. 31 Aug); Sunil Kataria appointed (eff. 1 Sep)GAVL leadership on board
3 Oct 2025Postal ballot notice: Kataria appointment; Dhekne and Gupte re-appointment; RPTsGovernance
29 Oct 2025Q2 FY26: income ₹74.8 crore (−26% YoY), loss ₹24.4 croreCDMO trough quarter
7 Nov 2025Postal ballot results declared — resolutions passed—
Nov–Dec 2025Multiple CP issuances at 6.73–7.00%Strong refinancing access despite losses
16 Jan 2026Announces participation in PMFAI ICSCE Dubai (19–20 Jan)Export customer outreach
30 Jan 2026Q3 FY26: income ₹125.5 crore (+31%), EBITDA +₹4.8 crore; CFO Khare resigns; Ochani named CFO from 1 AprFirst positive EBITDA in several quarters
24 Feb 2026577 ESOP shares allotted (ESOP 2012)Minor
9 Mar 2026Exit from Clean Max Andes (26%)Non-core clean-up
24 Mar 2026ICRA reaffirms AA- (Negative) / A1+Negative outlook retained
27 Mar 2026NCD interest of ₹4.36 crore paidDebt service on time
13 Apr 2026Leadership transition: Nadir Godrej retires as Chair; Vishal Sharma Chair; Burjis Godrej steps down as MD; Arijit Mukherjee ED; Mathew Eipe ID; stock −3.9% to ₹634Strategic alignment with Godrej Chemicals
27 Apr 2026FY26 results: revenue ₹448.1 crore (+17.5%), EBITDA ₹0.5 crore, loss ₹80.9 crore; Q4 income ₹161.3 crore (+34%)Inflection year
1 May 20261,142 ESOP options grantedMinor
2–3 Jun 2026Postal ballot: four director appointments and ₹405 crore RPTs (GAVL ₹300 crore, GIL ₹105 crore)Parent dependence formalised
5–6 Jun 2026GM–HR resignsSenior management churn
10 Jun 2026India Ratings update (IND AA- on NCDs)—
23 Jun 2026GAVL confirms no encumbrance on Astec sharesPositive governance signal
4 Jul 2026Postal ballot passed—
9 Jul 2026FY26 Annual Report and AGM notice dispatched—
31 Jul 202632nd AGM; Q1 FY27 results: income ₹84.3 crore (−8%), EBITDA ₹0.1 crore, loss ₹18.7 crore; Enterprise +42%, CDMO −42%Seasonal Q1 now EBITDA-breakeven
~3 Aug 2026Stock opens ~17% higher at ₹691 after resultsMarket rewards loss reduction
14 Aug 2026Group-level: Pirojsha Godrej becomes GIL Chair; Burjis Godrej becomes GAVL ChairParent leadership change
18 Sep & 1 Oct 2026Exchange volume clarifications; company confirms nothing undisclosedElevated speculative trading
16 Oct 2026Board meeting called for 26 Oct 2026 to approve Q2/H1 FY27 resultsNear-term catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 6,770 Mn in FY2022 to INR 4,480 Mn in FY2026.
Astec LifeSciences Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations6,7706,2804,5803,8104,480

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.